The AYA Oncology Self-care Movement for ALL

This study is looking at how social media can help young people (ages 15-25) with acute lymphoblastic leukemia (ALL) remember to take their 6-mercaptopurine (a chemotherapy medicine). You could join if you have ALL, are taking 6-mercaptopurine, and have at least six months left of this treatment. You also need to speak and read English and have an active social media account. The study will test an educational website and social media messages (#AYAOSM) designed to improve how well you take your medicine. We'll know if the interventions are successful by tracking how consistently you take your medicine over six months.

Study design
This interventional study plans to include 200 participants aged 15-25. It will compare an educational website and social media messages to see their impact on medication adherence.
What's involved
You will complete a baseline questionnaire online and use an electronic monitor to track your 6-mercaptopurine adherence daily for six months. There will also be a 28-day run-in period where only adherence is monitored.
Compensation
Not stated in the trial record.
Follow-up
Your medication adherence will be monitored for six months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07724652

The AYA Oncology Self-care Movement

Not Yet Recruiting
NAAges 15–25InterventionalSupportive care
Northwestern University
~200 participants
Updated 2026-07-24 on ClinicalTrials.gov
What's tested:Educational Website#AYAOSM

At a glance

Recruiting sites
0 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Electronically-monitored Medication Adherence
Measured over 6-months
Acute Lymphobkastic Leukemia
Medication Adherence
4 sites across 3 states
Illinois2
Pennsylvania1
Texas1

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

15-25 years old
Diagnosed with acute lymphoblastic leukemia (ALL)
Taking 6-mercpatopurine (6-MP) as part of their maintenance treatment with at least 6-months remaining
Be able to speak and read English
Have at least one active social media account (e.g., Instagram, TikTok) or be willing to download a platform for the study
Endorse missing a 6-MP dose in the prior month and/or at least one adherence barrier.

Exclusion

Cognitive impairments that would limit ability to complete measures, determined by the medical team
  • Electronically-monitored Medication Adherence6-months

    6-mercaptopurine (6-MP) adherence will be assessed using a Medication Event Monitoring System (MEMS), an electronic pill bottle cap that records bottle openings with date and time stamps. Adherence will be calculated as the percentage of prescribed days with a recorded bottle opening (number of days with openings/number of prescribed days × 100). The primary analysis will evaluate the proportion of participants achieving the clinically meaningful threshold of ≥95% adherent.